Concurrent Chemoradiotherapy Should Remain Standard of Care for Locally Advanced NSCLC

Share this content:
Concurrent chemoradiotherapy should remain as standard of care for treatment of locally advanced NSCLC.
Concurrent chemoradiotherapy should remain as standard of care for treatment of locally advanced NSCLC.

Concurrent chemoradiotherapy alone should remain the standard of care for the treatment of patients with locally advanced non-small cell lung cancer (NSCLC), a new study published online ahead of print in the Journal of Clinical Oncology has shown. 

Researchers sought to assess the efficacy of consolidation chemotherapy with docetaxel plus cisplatin after concurrent chemoradiotherapy with the same agents in patients with locally advanced NSCLC.

Researchers enrolled 437 patients and randomly assigned them to receive either concurrent chemoradiotherapy alone (observation arm) or concurrent chemoradiotherapy followed by consolidation chemotherapy (consolidation arm).

All patients received concurrent chemoradiotherapy with docetaxel and cisplatin weekly for 6 weeks plus radiation. Patients in the consolidation arm received three additional cycles of of docetaxel and cisplatin on days 1 and 8 every 3 weeks.

RELATED: Final OS Results from the Phase 3 OPTIMAL Trial in EGFR-Positive NSCLC

Results showed that among the 420 evaluable patients, the median progression-free survival was 8.1 months in the observation arm compared with 9.1 months in the consolidation arm (HR = 0.91; 95% CI: 0.73, 1.12; P=0.36). 

Researchers found that median overall survival was 20.6 months in the observation arm and 21.8 months in the consolidation arm (HR = 0.91; 95% CI: 0.72, 1.25; P=0.44).

The findings demonstrate that consolidation chemotherapy with docetaxel plus cisplatin after concurrent chemoradiotherapy with weekly docetaxel and cisplatin failed to prolong progression-free survival compared with concurrent chemoradiotherapy alone in patients with locally advanced NSCLC.

Reference

  1. Ahn JS, Ahn YC, Kim J-H, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2014.60.0130.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs